Neoadjuvant ipilimumab–nivolumab superior to adjuvant nivolumab

Peter Sidaway
DOI: https://doi.org/10.1038/s41571-024-00916-9
IF: 78.8
2024-06-16
Nature Reviews Clinical Oncology
Abstract:Data from phase II trials indicate that patients with resectable melanoma are likely to derive benefit from neoadjuvant immune-checkpoint inhibitors (ICIs), and that those with a major pathological response (MPR, defined as ≤10% residual viable tumour material) are unlikely to require subsequent therapy. Now, data from the phase III NADINA trial confirm these findings, as well as the superiority of this approach over adjuvant therapy with an ICI. A total of 423 patients with resectable stage III melanoma were randomly assigned (1:1) to either 2 cycles of neoadjuvant ipilimumab plus nivolumab followed by surgery, or surgery followed by adjuvant nivolumab. Patients in the neoadjuvant group without an MPR to neoadjuvant therapy received adjuvant nivolumab or dabrafenib plus trametinib (for those with BRAF V600E/K mutations). Event-free survival (EFS) was the primary end point.
oncology
What problem does this paper attempt to address?